Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

 
Thumbnail
View
Date
2022-06-28
Author
IACOBONI, GLORIA ORCID
Rejeski, Kai ORCID
Villacampa Javierre, Guillermo ORCID
van Doesum, Jaap ORCID
CHIAPPELLA, ANNALISA ORCID
Bonifazi, Francesca ORCID
Camacho-Arteaga, Lina ORCID
Marin Niebla, Ana ORCID
Barba, Pere ORCID
untranslateduntranslateduntranslateduntranslateduntranslated

Show full item record
Keywords
Treatment; Mantle cell lymphoma; Relapsed
Bibliographic citation
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022 Jun 28;6(12):3606–10.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/9613
This item appears in following collections

The following license files are associated with this item: